

Supplementary Table 1. Sequences of siRNA used in the work

Gene name	Sense strand	Antisense strand
Mst1 (Stk4)	GAGccAAuAcuAuGAuuGAdTsdT	UcAAUcAuAGuAUUGGCUCdTsdT
Mst2 (Stk3) (#1)	uGGAcuAcuuuGAuAAGcAdTsdT	UGCUuAUcAAAGuAGUCcAdTsdT
Mst2 (Stk3) (#2)	ccuuGGcAuuAcuucuAuAdTsdT	uAuAGAAGuAAUGCcAAGGdTsdT
NF2 (#1)	AGuucAAGAGAcAcGcAAAdTsdT	UUGCGUGAUCUCUUGAACUdTsdT
NF2 (#2)	ucccGAAAAGGGuGAuAAAdTsdT	UUuAUcACCCUUUCGGGAdTsdT
Yap1	cGcuGAGuuccGAAAucuudTsdT	AAGAUUUCGGAACUcAGCGdTsdT
CK19	GucAGuGuGGAGGuGGAuudTsdT	AAUCcACCUCcAcACUGACdTsdT

Chemical modifications were introduced to stabilize siRNA *in vivo*, reduce off-target potential of the sense strand, and minimize immune response (2'-OMe modified nucleotides are in lower case, and phosphorothioate linkages are indicated by 's').

Supplementary Table 2. Parameters of serum chemistry in mice treated with different combinations of siRNA targeting Hippo pathway

	Triple siRNA	Triple siRNA + si-Yap1
Albumin, g/dl	3.68±0.25	2.83±0.24***
Direct bilirubin, mg/dl	0.59±0.41	0.02±0.01***
Total bilirubin, mg/dl	0.894±0.54	0.107±0.03***
Total bile acids, mg/dl	148.1±53.2	15.3±4.8***
Cholesterol, mg/dl	132.8±17.2	65.2±11.4***
HDL, mg/dl	38.3±5.27	31.4±7.2
LDL, mg/dl	33.9±8.16	12.7±2.47***
Glucose, mg/dl	185±16.7	222±41.23

*** p<0.001